NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VIVS
VivoSim Labs, Inc.
There isn't enough reported data to score VIVS yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
VIVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
VIVS's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
VIVS PE Valuation
VIVS has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
VIVS Forward outlook
There aren't enough analyst estimates for VIVS to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over VIVS on earnings quality, reporting a profit while its opponent remains loss making.
VIVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.51 | -666% |
| Q2 2026 | -$4.46 | -$4.38 |
| Q1 2026 | -$5.35 | -$3.65 |
| Q4 2025 | $1.87 | +$11.95 |
| Q3 2025 | $0.62 | +$13.22 |
| Q2 2025 | -$0.08 | +$16.36 |
| Q1 2025 | -$1.70 | +$17.50 |
| Q4 2024 | -$10.08 | +$16.08 |
VIVS has swung to a loss: it lost $3.51 per share over the past year, after a profit the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over VIVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over VIVS on profitability, with a higher operating margin.
VIVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $51K | +82% |
| Q2 2026 | $18K | -51% |
| Q1 2026 | $40K | -22% |
| Q4 2025 | $26K | +8.3% |
| Q3 2025 | $28K | -6.7% |
| Q2 2025 | $37K | -5.1% |
| Q1 2025 | $51K | +76% |
| Q4 2024 | $24K | +380% |
VIVS's revenue is recovering but still below its 2019 peak: $51,000 last quarter, up 82% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6502% | +2909 points |
| Q2 2026 | -15328% | -7449 points |
| Q1 2026 | -7968% | -1783 points |
| Q4 2025 | -10577% | +3873 points |
| Q3 2025 | -9411% | -717 points |
| Q2 2025 | -7878% | +804 points |
| Q1 2025 | -6184% | +4492 points |
| Q4 2024 | -14450% | +59150 points |
VIVS's operating margin was −6502% last quarter, up 2909 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
VIVS has the stronger cash trend. Its trailing FCF is up 15% versus its history, compared with NVO at down 14%.
VIVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.2M | +$704K |
| Q1 2026 | -$2.2M | -$203K |
| Q4 2025 | -$2.3M | -$470K |
| Q2 2025 | -$3.9M | -$957K |
| Q1 2025 | -$2M | +$636K |
| Q4 2024 | -$1.8M | +$1.7M |
| Q3 2024 | -$2.7M | +$521K |
| Q2 2024 | -$3M | +$2.3M |
VIVS has burned cash in almost every quarter: −$10M over the past year, against −$10M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over VIVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
VIVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +214% | +11.2M shares |
| 1 year | +557% | +13.9M shares |
| 3 years | +2165% | +15.7M shares |
| 5 years | +2777% | +15.9M shares |
| Available history | +2925% | +15.9M shares |
VIVS has 16M diluted shares, up 557% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
VIVS Net Leverage
VIVS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
VIVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.5 | Oversold |
| Stochastic | 3.0 | Oversold |
VIVS's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VIVS PE vs Healthcare Sector
| Metric | VIVS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VIVS has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over VIVS on trend strength, trading above more of its moving averages.
VIVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 18% below |
| 20 week MA | $0.33 | 58% below |
| 50 week MA | $1.18 | 88% below |
| 100 week MA | $1.95 | 93% below |
| 200 week MA | $8.06 | 98% below |
VIVS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over VIVS on returns for 2026, with the stronger performance.
VIVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $96.0 | $191.5 | +100% |
| 2021 | $191.5 | $48.2 | -75% |
| 2022 | $48.2 | $19.1 | -60% |
| 2023 | $19.1 | $13.3 | -30% |
| 2024 | $13.3 | $3.67 | -72% |
| 2025 | $3.67 | $2.01 | -45% |
| 2026 YTD | $2.01 | $0.14 | -93% |
VIVS has finished five years in a row lower, and it's down 93% so far in 2026.